glp 1 oral New GLP-1 Outperforms Semaglutide Novo Nordisk's oral GLP-1 drug
Description
Read our blog The Race to Redefine Obesity Treatment and discover why WEGOVY is winning in the WEGOVY versus SAXENDA battle WEGOVYStar Performer in Novo Nordisk Obesity Market As obesity continues to be a growing global health concern, WEGOVY has emerged as a game-changer in weight management
All formulations of Wegovy and Foundayo are approved but only the Zepbound KwikPen will be available
Int J Neurosci 133(5):473491
However, Mintel is an expert in predicting trends in market dynamics, innovation, and consumer behaviour
$1,300+ retail Zepbound: $349 cash-pay (via manufacturer program)
Frias, E
